APNHY (Aspen Pharmacare Holdings) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APNHY Aspen Pharmacare Holdings Ltd APNHY
70 GF Score
Price $9.52
GF Value $9.87
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Aspen Pharmacare Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aspen Pharmacare Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $370 Mil. Aspen Pharmacare Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $579 Mil. Aspen Pharmacare Holdings's annualized EBITDA for the quarter that ended in Jun. 2026 was $9 Mil. Aspen Pharmacare Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 101.23.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Aspen Pharmacare Holdings's Debt-to-EBITDA or its related term are showing as below:

APNHY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.1   Med: 4.82   Max: 50.37
Current: 50.37

During the past 13 years, the highest Debt-to-EBITDA Ratio of Aspen Pharmacare Holdings was 50.37. The lowest was 2.10. And the median was 4.82.

APNHY's Debt-to-EBITDA is ranked worse than
99.56% of 678 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs APNHY: 50.37

Aspen Pharmacare Holdings  (OTCPK:APNHY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Aspen Pharmacare Holdings Debt-to-EBITDA Related Terms

Aspen Pharmacare Holdings Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Aspen Pharmacare Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspen Pharmacare Holdings Debt-to-EBITDA Chart

Aspen Pharmacare Holdings Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.97 2.90 3.77 10.04

Aspen Pharmacare Holdings Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.77 3.89 14.91 20.72

APNHY vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspen Pharmacare Holdings Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aspen Pharmacare Holdings's Debt-to-EBITDA falls into.


APNHY
70GF Score
Aspen Pharmacare Holdings Ltd APNHY
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspen Pharmacare Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aspen Pharmacare Holdings's Debt-to-EBITDA for the fiscal year that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(370.47 + 579.439) / 179.764
=5.28

Aspen Pharmacare Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(370.47 + 579.439) / 9.384
=101.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.

Is Aspen Pharmacare Holdings (APNHY) Overvalued in 2026?

Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued. The current stock price of $9.52 is trading 3.5% below its estimated GF Value™ of $9.87. GuruFocus considers Aspen Pharmacare Holdings to be Fairly Valued.

Key valuation signals for APNHY:

  • Debt-to-EBITDA:
  • GF Value™: $9.87 vs. price of $9.52 (3.5% below fair value)
  • GF Score™: 70/100 with 10 warning signs

No single metric tells the full story. See the APNHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspen Pharmacare Holdings Business Description

Address Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
70GF Score

Get the complete analysis for APNHY

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.52
Price
$9.87
GF Value